Diabetes (type 1 and type 2) in children and young people: diagnosis and management – periodontal diseaseStatus:In developmentProgramme:NICE guidelineExpected publication date: 29 June 2022
Social, emotional and mental wellbeing in primary and secondary educationStatus:In developmentProgramme:NICE guidelineExpected publication date: 6 July 2022
Self harm: assessment, management and preventing recurrenceStatus:In developmentProgramme:NICE guidelineExpected publication date: 6 July 2022
Urinary tract infection in under 16s: diagnosis and managementStatus:In development | In consultationProgramme:NICE guidelineConsultation end date: 25 May 2022Expected publication date: 27 July 2022
Otitis media with effusion in under 12sStatus:In developmentProgramme:NICE guidelineExpected publication date: 28 September 2023
Maternal and child nutritionStatus:In developmentProgramme:NICE guidelineExpected publication date: 22 November 2023
Diabetes (type 1 and type 2) in children and young people: diagnosis and management - medicines for type 2 diabetes (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 3 January 2024
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in childrenStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)Status:In developmentProgramme:NICE guidelineExpected publication date: TBC
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vertebral body tethering for idiopathic scoliosis in children and young peopleStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Somatrogon for treating growth disturbance in children and young people aged 3 and over [ID5086]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Eflornithine for maintenance treatment of high-risk neuroblastoma after 1 therapy in people up to 21 years [ID4060]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC